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after Unrelated Cord Blood Transplantation
Makoto Yazaki,1 Yoshiko Atsuta,2 Koji Kato,3 Shunichi Kato,4 Shuichi Taniguchi,5
Satoshi Takahashi,6 Hiroyasu Ogawa,7 Yasuji Kouzai,8 Takeshi Kobayashi,9 Masami Inoue,10
Ryoji Kobayashi,11 Tokiko Nagamura-Inoue,12 Hiroshi Azuma,13 Minoko Takanashi,14
Shunro Kai,15 Masao Nakabayashi,16 Hidehiko Saito17 for the Japan
Cord Blood Bank NetworkIncidence and characteristics of early bacterial infection within 100 days after unrelated cord blood transplan-
tation (UCBT) were assessed for 664 pediatric and 1208 adult recipients in Japan. Cumulative incidence of
early bacterial infection at day 100 post-UCBTwas 11% (95% confidence interval [CI], 8%-13%) for children
and 21% (CI, 19%-24%) for adults (P\.0001). Early bacterial infection in adults had a significant impact on
mortality (hazard ratio [HR]5 2.1, CI, 1.7-2.6; P\.0001), although no significant risk factors were identified.
Multivariate analysis identified older age group (6-10, and 11-15 years versus 0-5 years of age) at transplant
(HR 5 2.0 and 2.7, CI, 1.1-3.5 and 1.4-4.9; P 5 .020 and .002, respectively) as an independent risk factor
of early bacterial infection for children. Early bacterial infection in children did not have a significant impact
on mortality when adjusted. Of 315 bacteremia, 74% were caused by Gram-positive microorganisms.
Pneumonia occurred in 39 patients including 13 cases of Stenotrophomonas maltophilia pneumonia. Early bac-
terial infection had a negative effect on survival for adults and the median day of development was 10 days after
transplant, suggesting that the prevention of bacterial infection in the very early post-UCBT phase is important.
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Infection is 1 of the major causes of morbidity and
mortality for patients undergoing bone marrow trans-
plantation (BMT) and peripheral blood stem cell
transplantation (PBSCT) [1,2]. Recently, use of cord
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440 Biol Blood Marrow Transplant 15:439-446, 2009M. Yazaki et al.In this paper, we report the results of our analysis
of early bacterial infections before day 100 following
UCBT in 1872 Japanese patients. We conducted this
analysis to investigate the incidence and timing of
infections, causative micro organisms, potential risk
factors of infections, and the influence of infection
on outcome.PATIENTS AND METHODS
Patients
Between September 1997 and September 2005,
2362UCBTprocedures were performed using a single
cord blood (CB) in 175 transplantation centers with
221 transplantation units supported by 11 CB banks
affiliated with the Japan Cord Blood Bank Network
(JCBBN) in Japan. The subjects analyzed were 1872
patients whose initial clinical report forms (CRFs),
completed 100 days after UCBT, were submitted to
the JCBBN. The clinical protocols for UCBT were
approved by the institutional review board of the
respective institutions. Patients underwent UCBT if
they had no human leukocyte antigen (HLA)-identical,
1 locus mismatched relative or anHLA-matched unre-
lated BM donor could not be identified within 6 to 8
weeks [11].Thepatients or their parents gave their con-
sent for UCBT after being informed of the potential
risks andbenefits of the procedure. All patients received
conditioning chemotherapy in the sterile unit with
high-efficiency particulate air filtration. The condi-
tioning regimen, acute graft-versus-host disease
(aGVHD) prophylaxis and prevention of bacterial
infections varied according to the institute’s policy
and type of disease, although most of the institutions
used oral polymyxin B or fluoroquinolone with
intravenous antibiotics to prevent bacterial infections.
Selection of Grafts
Searches for unrelated CB units were processed
through the JCBBN, where 25,803 CB units were
available in August 2006. Suitable CB in JCBBN was
selected by cell count of nucleared cell before freezing
and HLA compatibility between CB and patients.
Preferred unrelated CB units were those that matched
at least 4 of 6 HLA antigens, based on serologic typing
for class I HLA-A and HLA-B, antigens and low-reso-
lutionDNA typing for class IIHLA-DR and contained
a minimum cell count of 2  107/kg nucleated cells of
the recipient’s body weight before freezing.
Bacterial Infections
We analyzed bacterial infections reported in the
JCBBN 100-day CRF with clinical symptoms and
pathogenic micro-organisms were discovered, be-
cause it is not easy to distinguish bacteremia or pneu-
monia without microbiologically documented infectionfrom preengraftment fever or capillary leak syndrome
in the early post-UCBT phase.
Early bacterial infections were defined as those
occurring within the first 100 days after graft infusion.
If a second episode with the same organism occurred
within 7 days, it was counted as a single infection
episode [10].
Collection of Data
Detailedpatient andclinical variableswere collected
by the JCBBNCRF. Its 100-day CRFs were submitted
by transplantation centers or units to the 11 CB banks
and checked by a data manager of each bank for missing
data and inconsistent data. After the data cleaning, all
CRFs were submitted fromCB banks to the data center
of JCBBN. Annual follow-up for each transplant case is
performed to update the data on engraftment, relapse,
survival, and complications. The final data set used for
the analyses was fixed in March 2006.
Statistical Analysis
Because preliminary study of all patients revealed
that 16 years of age and older was the sole significant
variable in multivariate analysis, separate analyses
were performed for children (younger than 16 years
of age) and adults (16 years of age and older) to find
the risk factors and to investigate the impact of infec-
tion on survival. All episodes of infectionwere included
in the analyses to identify causativemicro-organisms of
infections. Various clinical factors were evaluated as
potential risk factors for early bacterial infection in
univariate and multivariate analyses combined with
the Cox proportional-hazards regression model. Fac-
tors found to be significant (P \ .05) or marginally
significant (P\ .1) in univariate analysis were included
in the multivariate analysis using a forward stepwise
method. The categorization for the analyses of risk
factors was based on the rule that the smaller group
of variable needed to contain at least 10% of the
patients. The proportional hazards regression model
with early bacterial infection as a time-dependent cova-
riate was used to determine the effect of early bacterial
infection on survival. Survival distributions were esti-
mated with themethod ofKaplan andMeier. Probabil-
ities of early bacterial infection were calculated by
means of cumulative incidence curves treating death
without early bacterial infection as competing risks.
Statistical analyses were performed with Stata software
version 9.0 (Stata Corp., College Station, TX).RESULTS
Characteristics of Patients
Table 1 shows the characteristics of 664 pediatric
(age\16 years) and 1208 adult (age$16 years) patients
who underwent UCBT in Japan. In the child cohort,
Table 1. Characteristics of Pediatric and Adult Patients Who Received Unrelated Cord Blood Transplantation
Variable Child (Age <16) No. Eval (n 5 664) Adult (age $16) No. Eval (n 5 1208)
Sex—no. (%)
Male 664 403 (61)* 1208 662 (55)
Female 261 (39) 546 (45)
Age group—no. (%)
0-15 664 664 1208
16-30 270 (22)
31-45 338 (28)
$46 600 (50)
Disease—no. (%)
Acute lymphoblastic leukemia 664 279 (42) 1207 211 (17)
Acute myelogenous leukemia 151 (23) 490 (41)
Adult T cell leukemia 0 65 (5)
Chronic myelogenous leukemia 8 (1) 69 (6)
Chronic lymphocytic leukemia 0 3
Myelodysplastic syndrome 15 (2) 103 (9)
MDS/MPD 20 (3) 7 (1)
Lymphoma 28 (4) 188 (16)
Myeloma 0 32 (3)
Solid tumor 27 (4) 6
Aplastic anemia 14 (2) 24 (2)
Immunodeficiency 47 (7) 1
Metabolic disease 25 (4) 0
Others 50 (8) 8 (1)
History of previous transplantation—no. (%)
No 664 556 (84) 1208 914 (76)
Yes 108 (16) 294 (24)
Conditioning regimen—no. (%)
Myeloablative 664 545 (82) 1208 579 (48)
Nonmyeloablative 99 (15) 621 (51)
Unknown 20 (3) 8 (1)
Total-body irradiation 664 350 (53) 1208 928 (77)
ATG/ALG 664 75 (11) 1208 38 (3)
Prophylaxis against GVHD
Cyclosporine based 630 401 (64) 1172 846 (72)
Tacrolimus based 199 (32) 312 (27)
Others 30 (5) 14 (1)
Methotrexate used 630 362 (57) 1172 582 (50)
Prednisolone used 630 161 (26) 1172 47 (4)
Mycophenolate mofetil used 630 2 1172 78 (7)
Nucleated cell dose/kg body weight—1027
Median 664 5.10 1208 2.53
Range 1.18-24.91 1.02-6.42
HLA compatibility(GVHD direction)—no./total no. (%)
Matched 656 162 (25) 1187 129 (11)
One-antigen mismatch 380 (58) 457 (39)
Two-antigen mismatch 106 (16) 577 (49)
Three-antigen or more mismatch 8 (1) 24 (2)
MDS/MPD indicates myelodyplasticsyndrome/myeloproliferative disease; ATG, antithymocyte globulin; ALG, antilymphocyte globulin; GVHD, graft-
versus-host disease; HLA, human leukocyte antigen.
*Figures in parentheses show percentages.
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tion. Myeloablative conditioning regimen was adminis-
tered to 545 patients (82%). Total body irradiation
(TBI) was administered to 350 of 664 patients
(53%) and 311 of 545 patients (57%) who received
a myeloabalative condition regimen. For GVHD pro-
phylaxis, cyclosporine (CsA)-based prophylaxis was
administered to 401 patients (64%), and tacrolimus-
based prophylaxis to 199 (32%). Methotrexate (MTX)
was used for GVHD prophylaxis for 362 patients
(57%), and prednisolone for 161 (26%). The median
dose of nucleated cells per kilogram of patient’s body
weight was 5.10 107. In the adult cohort, 600 patients
(50%)were 46 years old or older, and 294patients (24%)
had a history of previous transplantation. TBI wasadministered to 998 of 1208 patients (77%) and 504 of
579patients (87%)who received amyeloabalative condi-
tion regimen, and 621 patients (51%) were given a non-
myeloablative conditioning regimen [12-15].CsA-based
GVHD prophylaxis was administered to 846 patients
(72%), and tacrolimus-based prophylaxis to 312 patients
(27%). Themedian dose of nucleated cells per kilogram
of patient’s body weight was 2.53  107.Incidence and Timing of Early Bacterial
Infection
In the child cohort, 77 patients (12%) developed
early bacterial infection with a cumulative incidence
of 9% (95% confidence interval [CI] 7%-11%) at 50
Table 2. Patients with Early Bacterial Infections Who Re-
ceived Cord Blood Transplantation
Child (Age <16) Adult (Age $16)
Patients Episodes Patients Episodes
Bacteremia 65 68 218 247
Pneumonia 2 2 37* 38
Colitis 4 4 2 2
Urinary infection 0 0 2 2
Sinusitis 0 0 2 2
Meningitis 0 0 1 1
Catheter infection 0 0 1 1
Others 6 6 7 7
Total patients with infection in children and in adults were 77 and 260,
respectively.
Number Clostridium difficile colitis 3.
*Ten patients with bacteremia developed pneumonia as the second
bacterial infection.
442 Biol Blood Marrow Transplant 15:439-446, 2009M. Yazaki et al.days and 11% (CI 8%-13%) at 100 days posttransplant
(Figure 1). The median day of bacterial infection
development was 8 days (range: 0-100) posttransplant.
Seventy-five percent of early infection in children
occurred within 31 days post-UCBT. In the adult
cohort, the cumulative incidence of early bacterial
infection was 19% (CI 17%-21%) at 50 days and
21% (CI 19%-24%) at 100 days after UCBT. Early
bacterial infection on median day 10 (0-97) posttrans-
plant occurred in the 260 adult recipients (22%) with
75% of the events occurring within 25 days. Statistical
analysis demonstrated that the cumulative incidence of
early bacterial infection in adults was significantly
higher than that in children (P\ .0001).
The majority of early bacterial infections devel-
oped during neutropenia (in 80% of children and
80% of adults). The median day of early bacterial
infection development during neutropenia was 7 days
(range: 0-80 days) for children and 8 days (0-80 days)
for adults respectively, whereas the corresponding
figures for early bacterial infections after neutrophil
recovery were 55 days (20-100 days) and 46 days
(14-97 days), respectively.Table 3. Causative Micro organisms of the Early Bacteremia
following Cord Blood Transplantation
No. episodes (%)
Bacteremia 315
Gram-positives 234 (74)
Staphylococcus spp. 147 (47)
Enterococcus spp. 56 (18)
Sreptococcus spp. 19 (6)
Bacillius spp. 8 (3)Types of Infections
Of the total of 1872 patients, 337 (18%) suffered
from bacterial infections between day 0 and day 100
after UCBT, with 12% of children and 22% of adults
suffering from early bacterial infections. As shown in
Table 2, bacteremia was the most common infection
within the first 100 days. In the child cohort, 68 cases
of bacteremia, 2 of pneumonia, and 4 of colitis (2 of
Clostridium difficile colitis) developed, and in the adult
cohort, 247 cases of bacteremia, 38 of pneumonia,
2 of colitis (one of Clostridium difficile colitis), 2 each
of urinary infection and sinusitis, and 1 each of Bacillus
cereus meningitis and catheter infection. Of the 2180
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Figure 1. Cumulative incidence of early bacterial infection within
100 days following unrelated cord blood transplantation was 9% (95%
CI 7%-11%) at 50 days and 11% (CI 8%-13%) at 100 days posttransplant
for children. The corresponding values were 19% (CI 17%-21%) and 21%
(CI 19%-24%) for adults.adults with early bacteremia, 192 patients had 1 infec-
tion episode, 23 had 2, and 3 had 3 infection episodes.
Causative Micro organisms of Bacteremia
Of the 315 episodes of bacteremia, Gram-positive
micro organisms accounted for 234 (74%), and Gram-
negative micro organisms for 81 (26%) of the cases
(Table 3). Staphylococcus species (spp) were the most
common Gram-positive pathogens responsible for
147 of the bacteremia cases (47%), with coagulase-
negative Staphylococcus (CNS) detected in 111 of these
cases (76%). Staphylococcus epidermidis was the mostCorynebacterium spp. 2
Clostridium spp. 1
Mycobacterium tuberculosis 1
Gram-negatives 81 (26)
Pseudomonas aeruginosa 34 (11)
Acinetobacter spp. 7
Enterobacter cloacae 7
E. coli 5
Stenotrophomonas maltophilia 5
Burkholderia cepacia 4
Klebsiella pneumoniae 3
Chyseobacterium spp. 3
Alcaligenes xylosoxidans 2
Salmonella spp. 2
Serratia spp. 1
Morganella morganii 1
Leuconostoc spp. 1
Micrococcus spp. 1
Aeromonas hyrophila 1
Capnocytophaga spp. 1
Bacteroides fragilis 1
Provotella oralis 1
Fusobacterium necrophorum 1
Biol Blood Marrow Transplant 15:439-446, 2009 443Early Bacterial Infections after UCBTcommon CNS micro organism and was isolated in
94 cases. Staphylococcus aureus was isolated in 32 of
the 147 cases, and was reported as methicillin-resistant
Staphylococcus aureus (MRSA) in 25 of 32 (78%). Entero-
coccus spp was found in 56 cases (18% of all bacteremia
cases), with 23 cases of Enterococcus faecalis, 21 cases of
Enterococcus faecium, 1 case of Enterococcus gallinarum,
and 11 unidentified cases. Streptococcus spp was the
third most common Gram-positive pathogen (19
cases), with 15 cases of alpha-Streptococcus, 3 of Strepto-
coccus agalaciae, and 1 unidentified case. Streptococcus
mitis was found in 9 of the 15 alpha-Streptococci cases
(60%). Of the 81 cases with Gram-negative micro-
organisms, Pseudomonas aeroginosa was found in 34
cases, accounting for 11% of all bacteremia cases,
and Stenotrophomonas maltophillia in 5 cases. Anaerobic
Gram-negative organisms, such as Bacteroides fragilis
(n 5 1), Provotella oralis (n 5 1), and Fusobacterium
necrophorum (n 5 1), were also isolated.
We also investigated causative micro organisms of
early bacteremia that developed in children and adults
either during neutropenia or after neutrophil recovery.
The distribution of these micro organisms in all
groups was similar except for that of Stenotrophomonas
maltophillia and Enterococcus spp, with all 5 Stenotropho-
monas maltophilia bacteremias that had developed in
adults during neutropenia, the percentage of Enterococ-
cus spp. bacteremia having developed in adults during
neutropenia being 3.8 times higher than in children.
Causative Micro organisms of Pneumonia
Thirty-seven adults and 2 children developed bac-
terial pneumonia within the first 100 days after UCBT.
Bacterial pneumonia developed as the first infection in
29 of these patients and 10 developed bacterial pneu-
monia following bacteremia, 4 of them because of the
same micro organism that caused bacteremia and 6
because of a different micro organism. One patient
developed secondary pneumonia of Stenotrophomonas
maltophilia following MRSA pneumonia, which ac-
counted for a total of 40 episodes of early bacterial
pneumonia. Gram-positive and Gram-negative micro
organisms accounted for 50% each of the cases of bac-
terial pneumonia. The causative micro organisms of
pneumonia in adults were identified as Staphylococcus
aureus (n 5 6), CNS (n 5 8), Enterococcus spp. (n 5 3),
Corynebacterium spp (n 5 1), Pseudomonas aeruginosa
(n5 5), Burkholderia cepacia (n5 2), and Stenotrophomo-
nas maltophilia (n5 13). Eleven of the Stenotrophomonas
maltophilia pneumonias developed during neutropenia.
Outcome of Patients with Early Bacterial
Infection
Of the 43 patients who developed bacteremia with
shock, 32 (74%) died as did 143 of 240 (60%) of those
who developed bacteremia without shock. For patientswho developed early bacteremia, bacterial infection
was the main cause of death for 20 (47%) of the
patients with bacteremia with shock, and 55 (23%) of
the patients with bacteremia without shock. Pseudomo-
nas aeroginosa bacteremia caused a higher mortality,
because 73% of the patients with this type of bacter-
emia died. Bacterial infection was the main cause of
death for 53% patients who developed Pseudomonas
aeroginosa bacteremia. Twenty-six (70%) of the 37
adults who developed bacterial pneumonia died, as
did 18 (49%) of the 37 adults who developed early bac-
terial pneumonia because of bacterial infection.
Risk Factors for Early Bacterial Infection after
UCBT
Among the factors assessed as risk factors for early
bacterial infection for children, older age group (6-10
years, and 11-15 years versus 0-5 years of age) at trans-
plant (hazard ratio [HR]5 1.9 and 2.8, CI 1.1-3.3 and
1.6-5.1; P 5 .024 and P\ .0001, respectively), pres-
ence of prior hematopoetic stem cell transplantation
(HR 5 1.8, CI 1.1-3.1; P 5 .032), infusion of\5.10
 107 nucleated cells per kilogram of patient’s body
weight (HR 5 1.6, CI 1.0-2.6, P 5 .049), and use of
nonmyeloablative conditioning regimen (HR 5 1.8,
CI 1.0-3.2; P 5 .039) were identified as significant in
univariate analysis (Table 4). Use of prednisolone for
GVHD prophylaxis was identified as a marginal risk
factor (HR 5 1.6, CI, 1.0-2.7; P 5 .070) in univariate
analysis. Multivariate analysis identified older age
group (6-10 years, and 11-15 years versus 0-5 years
of age) at transplant (HR 5 1.96 and 2.66, CI, 1.11-
3.47 and 1.44-4.91; P 5 .020 and .002, respectively)
as an independent risk factor of early bacterial infec-
tion for children. Use of prednisolone for GVHD pro-
phylaxis was also identified as a marginal risk factor
(HR 5 1.63, CI 0.98-2.71; P 5 .062).
In the adult cohort, use of nonmyeloablative condi-
tioning regimen was not significant. Univariate analysis
results identified the use of tacrolimus for GVHD
prophylaxis as a marginal risk factor (HR 5 1.31, CI
1.0-1.7; P 5 .055) compared to the use of CsA for
GVHDprophylaxis (Table5).Thecumulative incidence
of early bacterial infection tended to be higher for pa-
tients in the adult cohort who received tacrolimus-based
GVHD prophylaxis compared to those who received
nontacrolimus GVHD prophylaxis (25%, 95% CI,
20%-30% versus 20%, 95% CI, 17%-24% at 100 days
posttransplant, P 5 .088). No significant risk factor for
early bacterial infection was identified in univariate anal-
ysis, so thatmultivariate analysiswas not performed.The
risk of early bacterial infection did not increase with age
in the adult cohort (Table 5).
Effect of Early Bacterial Infections on Survival
The probability of survival of children 6 months
and 2 years after UCBT was 70% (CI 66%-73%)
Table 4. Univariate Analysis for Risk of Early Bacterial
Infection in Children
Factor n HR 95% CI P value
Age at transplant (Years)
0-5 392 1.00
6-10 164 1.90 1.09-3.33 .024
11-15 107 2.84 1.60-5.05 <.0001
Prior HSCT
$1 prior HSCT 108/664 1.82 1.05-3.14 .032
Disease
Acute myelogenous leukemia 151 1.00
Acute lymphoblastic leukemia 279 0.89 0.49-1.62 .701
HLA disparity
$Two-antigens mismatch
for GVHD direction
114/656 0.82 0.42-1.61 .574
$Two-antigens mismatch
for rejection direction
121/655 0.76 0.39-1.48 .415
Number of cells infused*
CD34+ cell <1.42  105/kg 244/487 1.21 0.70-2.09 .494
Nucleated cell <5.10  107/kg 332/664 1.62 1.00-2.63 .049
Conditioning regimen
Myeloablative 545/664 1.00
Nonmyeloablative 99/664 1.82 1.03-3.23 .039
Myeloablative condition
with total body irradiation
331/664 1.24 0.78-1.99 0.368
Antithymocyte
globulin/antilymphocyte globulin
75/664 1.58 0.83-3.01 .164
GVHD prophylaxis
Cyclosporine based 401 1.00
Tacrolimus based 199 1.23 0.72-7.08 .451
Prednisolone not used 469 1.00
Prednisolone used 161 1.60 0.96-2.66 .070
Methotrexate not used 268 1.00
Methotrexate used 362 0.87 0.53-1.42 .580
Disease status of malignant disease
Standard disease† 215 1.00
Advanced disease‡ 308 1.03 0.61-1.76 .907
HSCT indicates hematopoietic stem cell transplantation; GVHD, graft-
versus-host diseasel; CI, confidence interval; HR, hazard ratio.
*Number of cells at freezing.
†Standard disease means first complete remission or first chronic phase
of maliganant disease.
‡Advanced disease means all others except standard disease.
Table 5. Univariate Analysis for Risk of Early of Early
Bacterial Infection Adults
Factor n HR 95% Cl P Value
Age at transplant (years)
16-30 270 1.00
31-45 338 0.85 0.59-1.21 .355
46-60 445 1.04 0.75-1.43 .834
$61 155 1.05 0.69-1.59 .838
Prior HSCT
$1 prior HSCT 294/1208 1.02 0.76-1.37 .881
Disease
Acute myelologenous leukemia 490 1.00
Aute lymphoblastic leukemia 211 0.90 0.63-1.29 .572
Lymphoma 188 1.23 0.87-1.77 .233
HLA disparity
$Two-antigens mismatch
for GVHD direction
601/1187 0.99 0.77-1.27 .937
$Two-antigens mismatch
for rejection direction
623/1187 0.92 0.71-1.17 .485
Number of cell infused *
CD34+ cell <0.80  105/kg 560/1130 1.18 0.90-1.51 .240
Nucleated cell <2.53  107/kg 608/1208 1.17 0.91-1.49 .224
Conditioing regiman
Myeloablative 579/1208 1.00
Nonmyeloablative 621/1208 1.21 0.95-1.55 .125
Myeloablative condition
with total body irradiation
504/1208 1.21 094-1.55 0.145
GVHD prophylaxis
Cyclosporine based 846 1.00
Tacrolimus based 312 1.31 0.99-1.72 .055
Methotrexate not used 590 1.00
Methotrexate used 582 0.84 0.66-1.08 .182
Disease status malignant disease
Standard disease† 427 1.00
Advanced disease‡ 739 1.10 0.58-1.44 .469
HSCT indicates hematopoietic stem cell transplantation; GVHD, graft-
versus-host disease; CI, confidence interval; HR, hazard ratio.
*Number of cell at freezing.
†Standard disease means first complete remission or first chronic phase
of maliganant disase.
‡Advanced disease means all other except standard disease.
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follow-up of survivors was 2.1 years (range: 0.07-7.5).
Bacterial infection was the main cause of death in
12 of the 77 pediatric recipients (16%) with early bac-
terial infection. Evaluation of early bacterial infection
as a time-dependent covariate for patient’s survival
showed statistical significance (HR 5 1.6, CI 1.2-2.2;
P 5 .005) in univariate analysis. When adjusted for
patient age, sex, disease status, presence of previous
transplant, transplanted cell dose, HLA disparity,
conditioning regimen, and GVHD prophylaxis, this
factor showed no significance (HR 5 1.5, CI 0.9-2.4;
P 5 .111) for children.
In the adult cohort, the probability of survival
6 months and 1 year posttransplant was 50% (CI 47%-
53%) and 41% (CI 38%-44%), respectively. The
median follow-up of survivors was 1.0 year (range:
0.05-6.2). Bacterial infectionwas themain causeof death
in 79 of the 260 adult recipients (30%) with early bacte-
rial infection.The analysis of the effects of early bacterialinfection showed statistical significance in univariate
analysis (HR5 2.1, CI 1.7-2.5; P\ .0001) as well as in
multivariate analysis (HR5 2.1, CI 1.7-2.6; P\ .0001)
adjusted for the same variables as for the child cohort.
Overall survival (OS) rates of children who devel-
oped bacterial infection during neutropenia 100 and
365 days after infection were 58% (95% CI 44%-
70%), and 40% (95% CI 27%-53%), respectively.
The corresponding rates for children who developed
bacterial infection after neutrophil recovery were
67% (95% CI,38%-85%) and 67% (95% CI 38%-
85%), respectively. In the adult cohort, the correspond-
ing rateswere 40% (95%CI 33%-47%) and 27% (95%
CI 20%-34%), for bacterial infection having developed
during neutropenia and 49% (95% CI 34%-63%) and
38% (95%CI 23%-52%) for after neutrophil recovery.
Because early bacterial infection, neutrophil recov-
ery, and aGVHD occur during the early phase after
transplant,weperformedmultivariate analyses by treat-
ing these variables as time-dependent variables for the
analysis of early bacterial infection in terms of status
of neutrophil recovery and status of aGVHD.
Biol Blood Marrow Transplant 15:439-446, 2009 445Early Bacterial Infections after UCBTMultivariate analyses revealed that early bacterial infec-
tion remained a significant risk factor for overall mor-
tality of adults (HR 5 2.05, CI 1.68-2.49; P\ .0001).
However, early bacterial infection did not affect child
mortality (HR5 1.32, CI 0.81-2.15; P5 .27). Neutro-
phil recovery was a significant risk factor for overall
child mortality (HR 5 0.43, CI 0.28-0.67; P\ .0001)
and adults (HR 5 0.47, CI 0.38-0.59; P\ .0001) after
adjustment for patient and transplant characteristics.
However, grade ii to iv aGVHD did not have an effect
on child mortality (HR5 1.00, CI 0.72-1.38; P5 .98)
and adults (HR 5 1.08, CI 0.89-1.32; P 5 .43). These
findings suggest that early bacterial infection is an inde-
pendent risk factor for overall mortality of adults.DISCUSSION
Bacterial infections remain a major complication
following UCBT. To the best of our knowledge, this
study of 664 pediatric and 1208 adult patients repre-
sents the largest study reported to date for the exami-
nation of early bacterial infection following UCBT.
The incidence of early bacterial infection for adult
patients was significantly higher than that for pediatric
patients. The median day of bacterial infection devel-
opment was 8 days in children and 10 days in adults
posttransplant, respectively.
Gram-positive organisms were predominant (74%)
in the cases of early bacteremia examined in our study.
Previous studies also reported that Gram-positive or-
ganisms were prominent in bacteremia following
UCBT [8,12]. In our large-scale study, Staphylococcus
epidermidis was the most common organism isolated
in 94 of the 147 Staphylococcus spp. cases, whereas
Staphylococcus aureus was isolated in 32 cases. Among
patients with bacteremia of Staphylococcus aureus,
MRSA was found in 78% of the patients. Enterococcus
spp. was the second most common Gram-positive
pathogen, with 23 cases of Enterococcus faecalis and 21
of Enterococcus faecium. The percentage of Enterococcus
spp. bacteremia in adults was 3.8 times higher than
that in children during neutropenia. Because carbape-
nems or vancomycin has been used in the past, vanco-
mycin-resistant Enterococcus faecalis or Enterococcus
faecium was found in some patients. Streptococcus spp.
was the third most common Gram-positive pathogen
(19 cases), 79% of which were accounted for by al-
pha-Streptococcus, with Streptococcus mitis being the
most common pathogen. Pseudomonas aeruginosa was
the most frequently occurring bacterium in Gram-
negative organisms.
Stenotrophomonas maltophilia was found in 13 of 37
(35%) adults who developed early bacterial pneu-
monia, and the condition of 75% of these patients
deteriorated in spite of intensive therapy. Eleven of
13 Stenotrophomonas maltophillia adult pneumoniasdeveloped during neutropenia. Stenotrophomonas mal-
tophilia is naturally resistant to penicillins, cephems ex-
cept ceftazidim and cefpiramide, aminoglycosides, and
carbapenems, therefore, antibiotics must be carefully
selected for the treatment of patients with bacteremia
or pneumonia caused by this bacterium.
For children, use of nonmyeloablative condition-
ing regimen was identified to be significant in univar-
iate analysis. It was somewhat surprising that the use of
nonmyeloablative conditioning in children was associ-
ated with a higher frequency of infections than in the
myeloablative treated patients. Because the standard-
ized JCBBN 100-day CRF do not include items for
identifying information on comorbidity such as the
recently introduced comorbidity index by Sorror
et al [16], we could not make adjustments for patients’
comorbidity status at transplant. We therefore cannot
rule out the possibility that high-risk patients with
organ failure and poor infectious defense were more
likely to have been treated with nonmyeloablative con-
ditioning, increasing risk of bacterial infections.
Multivariate analysis identified older age (6-10
years, and 11-15 years versus 0-5 years of age) at trans-
plant as an independent risk factor for early bacterial
infection in children, whereas univariate analysis re-
vealed that older age at transplant and infusion of
\5.10  107 nucleated cells per kilogram of patient’s
body weight were identified as significant. These find-
ings suggest that older age of children was a stronger
risk factor than the number of infused nucleated cells
per kilogram of patient’s body weight. Higher activity
of cell reproduction in younger children may be asso-
ciated with a low incidence of mucosal toxicity, thus
contributing to a lower risk of bacterial infection.
In adults, the incidence of early bacterial infection
was almost twice as high, 21% at 100 days posttrans-
plant compared to 11% for children. Although no spe-
cific risk factor was identified in adults, the prognostic
significance of early bacterial infection was clearly
identified in our analysis, thus indicating the impor-
tance of the prevention of early bacterial infection.
No tendency for risk to increase with age was observed
in individuals 16 years or older.
In conclusion, we analyzed the incidence of early
post-UCBT bacterial infection in pediatric and adult
patients. The incidence of early bacterial infection
for adult patients was significantly higher than that
for pediatric patients. The risk of early bacterial infec-
tion increased with age for individuals younger than
16 years, but not for those 16 years or older. Early bac-
terial infection had a negative effect on survival, espe-
cially in adults for whom the incidence of early
bacterial infection was 21% and the median day of
development was 10 days post transplant. These find-
ings suggest that the prevention of bacterial infection
during conditioning and the very early post-UCBT
phase is especially important. Prospective clinical
446 Biol Blood Marrow Transplant 15:439-446, 2009M. Yazaki et al.studies are needed to establish the better prophylaxis
against early bacterial infection.ACKNOWLEDGMENTS
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